In our study, 67.6% of breast cancer cases were ER+, similar to data published in SSA and parts of East Africa, but different from West Africa where studies have reported a low rate of ER+ cases (35%) and high triple negative subtypes [8]. This evidence concerns the gene ESR1 and breast carcinoma.